CN109991411A - 一种检测待测样本中目标抗体的免疫测定方法及其应用 - Google Patents
一种检测待测样本中目标抗体的免疫测定方法及其应用 Download PDFInfo
- Publication number
- CN109991411A CN109991411A CN201711476497.4A CN201711476497A CN109991411A CN 109991411 A CN109991411 A CN 109991411A CN 201711476497 A CN201711476497 A CN 201711476497A CN 109991411 A CN109991411 A CN 109991411A
- Authority
- CN
- China
- Prior art keywords
- antibody
- immune complex
- immune
- people
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000001514 detection method Methods 0.000 title claims abstract description 66
- 230000036039 immunity Effects 0.000 title claims abstract description 13
- 239000000427 antigen Substances 0.000 claims abstract description 84
- 108091007433 antigens Proteins 0.000 claims abstract description 84
- 102000036639 antigens Human genes 0.000 claims abstract description 84
- 210000002966 serum Anatomy 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 64
- 238000002965 ELISA Methods 0.000 claims description 51
- 239000003550 marker Substances 0.000 claims description 46
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 44
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 43
- 241001465754 Metazoa Species 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 40
- 241001515965 unidentified phage Species 0.000 claims description 34
- 238000003018 immunoassay Methods 0.000 claims description 25
- 239000007790 solid phase Substances 0.000 claims description 23
- 229960002685 biotin Drugs 0.000 claims description 21
- 235000020958 biotin Nutrition 0.000 claims description 21
- 239000011616 biotin Substances 0.000 claims description 21
- 210000004989 spleen cell Anatomy 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000011068 loading method Methods 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 108010090804 Streptavidin Proteins 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 14
- 239000012228 culture supernatant Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000002299 complementary DNA Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 241001529936 Murinae Species 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 7
- 230000005281 excited state Effects 0.000 claims description 7
- 150000001336 alkenes Chemical class 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 4
- 230000002186 photoactivation Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 3
- 150000002602 lanthanoids Chemical class 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 57
- 108020003175 receptors Proteins 0.000 description 42
- 208000002672 hepatitis B Diseases 0.000 description 26
- 239000000243 solution Substances 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 101710132601 Capsid protein Proteins 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 230000006058 immune tolerance Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 238000002649 immunization Methods 0.000 description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000003504 photosensitizing agent Substances 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000283986 Lepus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 2
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical group O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000003163 cell fusion method Methods 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N acridan acid Natural products C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 antibody Proteins 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Chemical group 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011856 silicon-based particle Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WHLUQAYNVOGZST-UHFFFAOYSA-N tifenamil Chemical group C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 WHLUQAYNVOGZST-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1106 | 0.1694 | 0.1403 | 0.1220 | 0.1446 | 0.1216 | 0.1267 | 0.1145 |
1000 | 0.1394 | 0.5199 | 0.3102 | 0.4200 | 0.3227 | 0.1721 | 0.1084 | 0.2842 |
100 | 0.9874 | 1.8699 | 1.3351 | 1.6106 | 1.3367 | 0.7115 | 0.5412 | 1.1412 |
10 | 1.5354 | 2.5083 | 2.4371 | 2.5663 | 2.5656 | 1.6474 | 1.5641 | 1.6241 |
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1124 | 0.1854 | 0.1547 | 0.1624 | 0.1154 | 0.1136 | 0.1101 | 0.1254 |
1000 | 0.3145 | 0.9654 | 0.6584 | 0.8541 | 0.4651 | 0.3895 | 0.1954 | 0.5412 |
100 | 1.3254 | 1.6741 | 1.4214 | 1.5821 | 1.2451 | 1.1874 | 0.8941 | 1.3512 |
10 | 2.5284 | 2.6541 | 2.6142 | 2.6421 | 2.5641 | 2.4254 | 1.5421 | 2.5142 |
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1074 | 0.5108 | 0.3250 | 0.3951 | 0.2055 | 0.1487 | 0.1243 | 0.2141 |
1000 | 0.6254 | 1.7009 | 1.3473 | 1.5012 | 1.0031 | 0.6207 | 0.3089 | 1.1254 |
100 | 1.9421 | 2.6115 | 2.5272 | 2.5142 | 2.3392 | 1.8743 | 1.1943 | 2.3241 |
10 | 2.6521 | 2.6685 | 2.6057 | 2.5254 | 2.6493 | 2.6583 | 2.0444 | 2.5214 |
Claims (34)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711476497.4A CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711476497.4A CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109991411A true CN109991411A (zh) | 2019-07-09 |
CN109991411B CN109991411B (zh) | 2023-01-20 |
Family
ID=67108802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711476497.4A Active CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109991411B (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007271A1 (en) * | 1988-01-28 | 1989-08-10 | E.I. Du Pont De Nemours And Company | Immunoassays using monoclonal antibodies directed against natural binding proteins |
US4925788A (en) * | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
JPH08193999A (ja) * | 1995-01-13 | 1996-07-30 | Sekisui Chem Co Ltd | 免疫測定法 |
US20100081212A1 (en) * | 2008-09-30 | 2010-04-01 | Matthias Ehm | Antibodies for determining the prothrombin fragment f2/f1+2 in a homogeneous immunoassay |
US20120157663A1 (en) * | 2008-05-20 | 2012-06-21 | Tokyo University Science | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
CN102735833A (zh) * | 2012-07-09 | 2012-10-17 | 沃克(天津)生物科技有限公司 | 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法 |
CN102944672A (zh) * | 2012-11-16 | 2013-02-27 | 李方和 | 采用光激发化学发光免疫分析对血清中的待测靶物质进行定性与定量检测的方法 |
CN103217533A (zh) * | 2012-01-21 | 2013-07-24 | 厦门大学 | Anti-HBc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
CN105758835A (zh) * | 2016-05-04 | 2016-07-13 | 成都爱兴生物科技有限公司 | 一种均相免疫分析poct检测技术及使用该技术的系统 |
CN105785030A (zh) * | 2016-03-09 | 2016-07-20 | 博阳生物科技(上海)有限公司 | 一种血清特异性IgE光激化学发光免疫分析试剂盒 |
CN106596958A (zh) * | 2016-12-19 | 2017-04-26 | 中国兽医药品监察所 | 布鲁氏菌病cf‑elisa抗体检测试剂盒 |
CN106699883A (zh) * | 2016-12-19 | 2017-05-24 | 中国兽医药品监察所 | 豚鼠补体C1q‑B单克隆抗体60G4的制备与应用 |
-
2017
- 2017-12-29 CN CN201711476497.4A patent/CN109991411B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925788A (en) * | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
WO1989007271A1 (en) * | 1988-01-28 | 1989-08-10 | E.I. Du Pont De Nemours And Company | Immunoassays using monoclonal antibodies directed against natural binding proteins |
JPH08193999A (ja) * | 1995-01-13 | 1996-07-30 | Sekisui Chem Co Ltd | 免疫測定法 |
US20120157663A1 (en) * | 2008-05-20 | 2012-06-21 | Tokyo University Science | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
US20100081212A1 (en) * | 2008-09-30 | 2010-04-01 | Matthias Ehm | Antibodies for determining the prothrombin fragment f2/f1+2 in a homogeneous immunoassay |
CN103217533A (zh) * | 2012-01-21 | 2013-07-24 | 厦门大学 | Anti-HBc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
CN102735833A (zh) * | 2012-07-09 | 2012-10-17 | 沃克(天津)生物科技有限公司 | 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法 |
CN102944672A (zh) * | 2012-11-16 | 2013-02-27 | 李方和 | 采用光激发化学发光免疫分析对血清中的待测靶物质进行定性与定量检测的方法 |
CN105785030A (zh) * | 2016-03-09 | 2016-07-20 | 博阳生物科技(上海)有限公司 | 一种血清特异性IgE光激化学发光免疫分析试剂盒 |
CN105758835A (zh) * | 2016-05-04 | 2016-07-13 | 成都爱兴生物科技有限公司 | 一种均相免疫分析poct检测技术及使用该技术的系统 |
CN106596958A (zh) * | 2016-12-19 | 2017-04-26 | 中国兽医药品监察所 | 布鲁氏菌病cf‑elisa抗体检测试剂盒 |
CN106699883A (zh) * | 2016-12-19 | 2017-05-24 | 中国兽医药品监察所 | 豚鼠补体C1q‑B单克隆抗体60G4的制备与应用 |
Non-Patent Citations (8)
Title |
---|
ERIC J. BROWN ET AL.: "NEOANTIGENS APPEAR IN HUMAN IgG UPON ANTIGEN BINDING: DETECTION BY ANTIBODIES THAT REACT SPECIFICALLY WITH ANTIGEN-BOUND IgG", 《THE JOURNAL OF IMMUNOLOGY》 * |
JOSEPH BEKISZ等: "A MOUSE MONOCLONAL ANTIBODY THAT REACTS SPECIFICALLY WITH IMMUNE-COMPLEXED HUMAN IgG", 《MOLECULAR IMMUNOLOGY》 * |
吕世静等: "《临床免疫学检测》", 31 August 2015 * |
吴梧桐: "《生物制药工艺学》", 30 April 2013 * |
王云英等: "《临床免疫学检验》", 31 March 2009 * |
王岚: "《病原生物学与免疫学基础》", 31 August 2012 * |
组织细胞分子学实验原理与方法: "《组织细胞分子学实验原理与方法》", 30 September 2003 * |
陈桂兰等: "光激化学发光免疫分析法测定低浓度HBsAg效果评价", 《重庆医学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109991411B (zh) | 2023-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108051585B (zh) | 一种均相免疫检测试剂盒、检测方法及其应用 | |
CN109709317B (zh) | 一种无基质效应的均相免疫检测试剂盒及其分析方法和应用 | |
JPS59183696A (ja) | 架橋フイブリン誘導体特異性モノクロ−ナル抗体 | |
CN107102135A (zh) | 用于减少非特异性结合的免疫检验方法和试剂 | |
CN114217076B (zh) | 检测目标抗-Carp抗体的均相免疫检测试剂盒及其应用 | |
US20180372638A1 (en) | Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample | |
CN109725153A (zh) | 一种均相免疫检测方法及其应用 | |
CN108169497A (zh) | 人泌乳素检测试剂盒及其制备方法与应用 | |
CN109991405A (zh) | 一种免疫检测试剂盒及其应用 | |
CN110161247A (zh) | 检测抗环瓜氨酸肽抗体的均相免疫检测试剂盒及其应用 | |
CN106632691A (zh) | Hiv重组抗原、表达基因、表达载体以及hiv检测试剂盒 | |
CN112094352B (zh) | 一种抗IgM单克隆抗体 | |
Li et al. | Highly efficient and precise two-step cell selection method for tetramethylenedisulfotetramine-specific monoclonal antibody production | |
CN109991411A (zh) | 一种检测待测样本中目标抗体的免疫测定方法及其应用 | |
CN109988241A (zh) | 一种特异性识别人免疫复合物的抗体及其制备方法和用途 | |
CN114397442A (zh) | 检测14-3-3eta蛋白的均相免疫检测试剂盒及其应用 | |
CN103185803A (zh) | 一种鉴定抗体敏感性和克隆细胞株的方法及试剂盒 | |
CN110161248B (zh) | 检测抗Carp抗体的均相免疫检测试剂盒及其应用 | |
CN111217910B (zh) | 单克隆抗体对及其在检测髓过氧化物酶蛋白中的应用 | |
CN110161232B (zh) | 检测抗ccp抗体的均相免疫检测试剂盒及其应用 | |
JP4663831B2 (ja) | モノクローナル抗体、細胞株及びn1,n12−ジアセチルスペルミンの測定法 | |
CN106929477B (zh) | 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用 | |
JPH01153960A (ja) | 赤血球凝集アッセイ | |
TW562925B (en) | Immunogenic compositions for use in immunoassay methods to measure diacyl hydrazines or derivatives thereof and antibodies raised by the same, and methods and kits of measuring diacyl hydrazines or derivatives thereof | |
CN106520703A (zh) | 拟柱孢藻毒素单克隆抗体杂交瘤细胞及单克隆抗体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201210 floor 3 and 5, building 1, No. 88, Cailun Road, free trade zone, Pudong New Area, Shanghai Applicant after: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant after: Kemei Diagnostic Technology Co.,Ltd. Address before: 201210 Shanghai City, Pudong New Area Free Trade Zone No. 88 five floor East Cailun Road Applicant before: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant before: BEIJING CHEMCLIN BIOTECH Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yinghao Inventor after: Zhao Weiguo Inventor after: Liu Yuhui Inventor after: Li Lin Inventor before: Chen Yinghao Inventor before: Zhao Weiguo Inventor before: Li Huiqiang Inventor before: Liu Yuhui Inventor before: Li Lin |
|
CB02 | Change of applicant information |
Address after: 200131 third and fifth floors, building 1, No. 88 Cailun Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: Kemei Boyang diagnostic technology (Shanghai) Co.,Ltd. Applicant after: Kemei Diagnostic Technology Co.,Ltd. Address before: 201210 third and fifth floors, building 1, No. 88, Cailun Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant before: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant before: Kemei Diagnostic Technology Co.,Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221021 Address after: 201210 East floor, first floor, building 7, No. 249 Faraday Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: SHANGHAI SUOXIN BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 200131 3rd and 5th floors, building 1, No.88 Cailun Road, Pudong New Area pilot Free Trade Zone, Shanghai Applicant before: Kemei Boyang diagnostic technology (Shanghai) Co.,Ltd. Applicant before: Kemei Diagnostic Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |